sibutramine

[si-bu´trah-mēn″] an appetite suppressant used as the hydrochloride salt in treatment of obesity; administered orally.

sibutramine

(sə-byo͞o′trə-mĭn, -mēn′)n. A drug formerly used in the management of obesity, withdrawn from the US market in 2010 because of its association with an increased risk of heart attacks and strokes.

sibutramine

A central, appetite-suppressing agent that blocks reuptake of serotonin, norepinephrine and, to a lesser extent, dopamine; it provides a sensation of fullness from lesser amounts of food, and increases metabolism. Sibutramine was approved for use as a dietary adjunct in the mid-1990s and was heavily marketed until 2010, when it was withdrawn from the market due to the increased risk of cardiovascular events and strokes associated with its use. Sibutramine is a Schedule-IV Controlled Substance.

Indications
Obese patients with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 in addition to other factors (e.g., hypertension, diabetes, dyslipidemia).
Adverse effects
Headache, dry mouth, anorexia, constipation.
Contraindications
Concurrent MAOIs, other central appetite suppressants, anorexia nervosa.

sibutramine

Meridia^® Obesity A central, appetite-suppressing agent that blocks reuptake of serotonin and norepinephrine, and, to a lesser extent dopamine; it provides a sensation of fullness from less food, and ↑ metabolism Indications Obese Pts with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 with other factors–eg, HTN, DM, dyslipidemia Cons Sibutramine is a Schedule IV Controlled Substance Adverse effects Headache, dry mouth, anorexia, constipation Contraindications Concurrent MAOIs, other central appetite suppressants, anorexia nervosa. See Obesity.

si·bu·tra·mine

(si-byū'tră-mēn) A serotonin and noradrenaline reuptake inhibitor used to reduce appetite to encourage weight loss.

sibutramine

An antiobesity drug that acts on the nervous system in a manner similar to that of Prozac so that the patient is able to feel satisfied with smaller amounts of food. The drug is not recommended for people under 18 and is used for a maximum period of one year. It is prescribed mainly for those with a body mass index (BMI) of 30 or over. Brand name Reductil.

Sibutramine

An appetite-suppressing drug that may increase the activity of norepinephrine and serotonin in the brain.Mentioned in: Weight Loss Drugs

si·bu·tra·mine

(si-byū'tră-mēn) A serotonin and noradrenaline reuptake inhibitor used to reduce appetite to encourage weight loss.

单词	sibutramine
释义	sibutramine si·bu·tra·mine S0383775 (sə-byo͞o′trə-mĭn, -mēn′)n. A drug formerly used in the management of obesity, withdrawn from the US market in 2010 because of its association with an increased risk of heart attacks and strokes. [Alteration of cy(clo)- + but(yl) + perhaps (t)r(i)- (from its three methyl groups) + amine.] Translations sibutramine sibutramine [si-bu´trah-mēn″] an appetite suppressant used as the hydrochloride salt in treatment of obesity; administered orally. sibutramine (sə-byo͞o′trə-mĭn, -mēn′)n. A drug formerly used in the management of obesity, withdrawn from the US market in 2010 because of its association with an increased risk of heart attacks and strokes. sibutramine A central, appetite-suppressing agent that blocks reuptake of serotonin, norepinephrine and, to a lesser extent, dopamine; it provides a sensation of fullness from lesser amounts of food, and increases metabolism. Sibutramine was approved for use as a dietary adjunct in the mid-1990s and was heavily marketed until 2010, when it was withdrawn from the market due to the increased risk of cardiovascular events and strokes associated with its use. Sibutramine is a Schedule-IV Controlled Substance. Indications Obese patients with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 in addition to other factors (e.g., hypertension, diabetes, dyslipidemia). Adverse effects Headache, dry mouth, anorexia, constipation. Contraindications Concurrent MAOIs, other central appetite suppressants, anorexia nervosa. sibutramine Meridia^® Obesity A central, appetite-suppressing agent that blocks reuptake of serotonin and norepinephrine, and, to a lesser extent dopamine; it provides a sensation of fullness from less food, and ↑ metabolism Indications Obese Pts with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 with other factors–eg, HTN, DM, dyslipidemia Cons Sibutramine is a Schedule IV Controlled Substance Adverse effects Headache, dry mouth, anorexia, constipation Contraindications Concurrent MAOIs, other central appetite suppressants, anorexia nervosa. See Obesity. si·bu·tra·mine (si-byū'tră-mēn) A serotonin and noradrenaline reuptake inhibitor used to reduce appetite to encourage weight loss. sibutramine An antiobesity drug that acts on the nervous system in a manner similar to that of Prozac so that the patient is able to feel satisfied with smaller amounts of food. The drug is not recommended for people under 18 and is used for a maximum period of one year. It is prescribed mainly for those with a body mass index (BMI) of 30 or over. Brand name Reductil. Sibutramine An appetite-suppressing drug that may increase the activity of norepinephrine and serotonin in the brain.Mentioned in: Weight Loss Drugs si·bu·tra·mine (si-byū'tră-mēn) A serotonin and noradrenaline reuptake inhibitor used to reduce appetite to encourage weight loss.
随便看	iated iatefl iatepc i ate your microphone iedn ie domain registry iedp i/edr iedr iedrc iedro iedrr ieds iedss iedt iedta iedw iedz ie&e iee ieea ieeac ieeaf ieeb ieec